Featured News
October 30, 2026
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
October 13, 2026
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Our Commitment to Responsibility
At Alkermes, we are committed to making a difference not only in the lives of people living with complex psychiatric and neurological disorders, but also in the communities in which we live and work. We seek to operate our business ethically and grow our organization in a responsible and sustainable manner. Our most recent Corporate Responsibility Report details our efforts.
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Establishing Alkermes’ Leadership in Sleep Medicine
Hear from Blair Jackson on Alkermes’ acquisition of Avadel Pharmaceuticals plc.
Great Science: Orexin’s Applications in ADHD
Ishani Landry shares why she is passionate about helping advance Alkermes’ orexin development program.
Honoring our 2026 HBA Luminary
Janine Shea, Alkermes’ 2026 HBA Luminary honoree, reflects on her career journey and leadership philosophy and shares advice for women building careers in life sciences.
Media Resources
Company Description
Alkermes applies its decades of deep neuroscience expertise to develop medicines designed to help people living with complex, chronic psychiatric and neurological disorders. A global biopharmaceutical company headquartered in Dublin, Ireland, with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of important new medicines in areas which are often overlooked, including addiction, serious mental illness and sleep disorders.
Follow us on our social channels
